drugset / Trial / NCT04418141
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
Phase 1
Completed
13 enrolled
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma. This study will provide a basis for further clinical development of CN1.
Timeline
- Start
- 2020-07-02
- Primary completion
- 2021-10-07
- Completion
- 2021-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CN1 | Unknown | 0.03 mg/kg | Intravenous |
| Subject | CN1 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | CN1 | Unknown | 1 mg/kg | Intravenous |
| Subject | CN1 | Unknown | 3 mg/kg | Intravenous |
| Subject | CN1 | Unknown | 10 mg/kg | Intravenous |